Novo Nordisk’s Costly Oversight: A Billion-Dollar Lesson in Negligence
Novo Nordisk faces billions in losses over a missed payment of just a few hundred dollars, exposing a critical oversight. This blunder could cost the pharmaceutical giant its market edge, serving as a stark reminder of the high stakes of negligence in business.